-
Loading metrics
EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong – A cost-effectiveness analysis
- Joyce H. S. You,
- William C. S. Cho,
- Wai-kit Ming,
- Yu-chung Li,
- Chung-kong Kwan,
- Kwok-hung Au,
- Joseph Siu-kie Au
x
- Published: March 1, 2021
- https://doi.org/10.1371/journal.pone.0247860